- RBC Capital downgraded EyePoint Pharmaceuticals (NASDAQ:EYPT) due to mixed Phase 3 trial results for its wet AMD drug, DURAVYU.
- The LUGANO trial for DURAVYU missed its primary endpoint, influenced by a small patient subgroup, despite showing comparable efficacy to standard treatment and a 42% reduction in treatment burden in a separate analysis.
- EyePoint's stock plummeted over 66.98% to a 52-week low of $3.95, further pressured by positive trial data from competitor REGENXBIO (NASDAQ:RGNX) for its own wet AMD treatment.
RBC Capital downgrades its rating on EyePoint Pharmaceuticals to Sector Perform from a previous Outperform rating. EyePoint is a pharmaceutical company that develops treatments for serious eye disorders. The downgrade occurs as the stock price is $4.87, following a significant drop related to recent company news.
The change in rating follows the release of mixed results from EyePoint's Phase 3 LUGANO clinical trial for its drug, DURAVYU. This trial tested the drug's effectiveness in treating wet age-related macular degeneration (AMD), a common cause of vision loss. As highlighted by Reuters, the study did not meet its main goal.
The trial's primary objective was not met due to a small group of patients. This group, representing 4% of participants, had vision loss from causes unrelated to wet AMD. This unexpected outcome affected the overall data for the study's main test, preventing it from showing a clear benefit on vision.
However, a separate analysis that excluded this small group showed DURAVYU performed as well as the current standard treatment, aflibercept. The trial also showed other positive results, including a 42% reduction in treatment burden. This means patients using DURAVYU required fewer treatments over time compared to the standard drug.
The market reacted strongly to the news, with EyePoint shares falling 66.98% to a new 52-week low of $3.95 during the day. At the same time, a competitor, REGENXBIO, announced positive trial data for its own wet AMD treatment, adding pressure to the competitive environment for EyePoint.
